RxDoctor Payments Data

Stanley Conhon, MD

Family Medicine · Davison, MINPI 1487642575

Payments from drug & device makers

$10,013in general payments, 2019–2025

Across 559 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • GSK$972
  • Amgen$677
  • Novo Nordisk$589
  • Boehringer Ingelheim$336
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,95299%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,013 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$48,539
Medicare patients
217
Services billed
1,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide148$215,414
JardianceEmpagliflozin144$204,863
OzempicSemaglutide141$192,301
Trelegy ElliptaFluticasone/Umeclidin/Vilanter185$166,405
EliquisApixaban147$157,138
RybelsusSemaglutide62$122,907
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$40,583
FarxigaDapagliflozin Propanediol29$39,788
RexultiBrexpiprazole23$36,642
TrulicityDulaglutide35$33,463
Combivent RespimatIpratropium/Albuterol Sulfate40$24,096
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$20,138
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$19,923
MyrbetriqMirabegron20$16,926
WegovySemaglutide12$15,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$589$330,642215 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$191$252,712200 claims
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat$336$242,091209 claims
GSKTrelegy Ellipta, Anoro Ellipta$972$174,227196 claims
PfizerEliquis$309$157,138147 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,829$80,37181 claims
Otsuka America Pharmaceutical, Inc.Rexulti$177$36,64223 claims
Astellas Pharma US IncMyrbetriq$154$16,92620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Davison

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →